@haidut said in High-fat/low-carb diet causes systemic inflammation, impairs gut barrier, aggravates inflammatory bowel disease (IBD):

Unfortunately, I cannot get access to the full study

Anyone wanting to access the study without individual payment needs to get his/her ass to a university library computer equipped with Shibboleth access.

@cs3000 said in Oxidative metabolism reflects our biological age, metabolic dysfunction drives frailty/aging:

neutrophil - lymphocyte ratio is a common marker of poor health,

I have this high ratio myself, yet I consider having it high, with the latest CBC showing 66% to 21%, or higher than a 3:1 ratio. But I've had this way 25 yrs ago, coinciding with the time my blood pressure started going up from the safe value of 120/80.

But I have been healthy despite the high BP, which I never (until 2 yrs ago) treated with hypertensive prescription drugs (until I had to when I developed heart failure and had to go to the ICU after my heart stopped and I had to be revived at the ER). I'm saying this because I developed heart failure not because of high BP, but because I had allowed a self-induced bronchitis to be taken for granted and the hypoxemia that was left unresolved cascaded into heart failure. I say this to emphasize that it wasn't my high BP, as left un- intervened by hypertensive drugs, that caused it.

If only to support my contention that a high neutrophil/lymphocyte ratio, in my experience, while not ideal, was something tolerable, though it definitely was associated with my high BP situation. Because during that time, I wasn't suffering from any issues. This meant zero allergies, no flu for the past 25 years (nor fever), which I would say counts for high immunity. No body aches, stomach aches nor headaches. No overweight, great sugar control, normothyroid. High endurance running, and an ability to dry fast for 3 days. Also high internal metabolism, which did not require me to work out or walk to maintain s normal weight. Which meant, despite (or because of) high BP, I was very healthy.

But I have lead toxicity, and a low grade (ie no fever) internal infection I attribute to a periodontal infection that translocated, both of which persisted and caused a continual immune response that produced a persistent level of oxidative stress. Which caused my high BP.

The high BP came from having low blood volume that my body had to increase BP to compensate for, in order to ensure the lower blood volume can still provide adequate circulation and perfusion of blood through the tissues and organs without fail.

The low blood volume resulted from lower serum albumin, which was lower from its being used daily as an extracellular antioxidant to counter the oxidative stress arising from spillover ROS resulting from the immune system creating ROS to kill pathogenic microbes that was never totally eliminated, as well as the oxidative stress from the lead toxicity that never got resolved as well.

But I could not say my immune system was overactive and dysfunctional. It did what it had to do to protect me from lead toxicity and periodontal infection that needed more external intervention (heavy metal chelation and use of better methods of infection control other than pharma antibiotics) in order to eliminate.

Through it all, I had high BP which did not cause my health to deteriorate (I feel high BP was a protective adaptation though our doctors would say otherwise), and the albumin that was constantly being used up and lost, was a renewable resource in the sense that the liver kept producing more of it to replace the ones used. In this way, my body was kept from suffering any tissue destruction that may have resulted from the constant oxidative stress from heavy metal toxicity and spillover ROS my immune system generates. My tissues and organs are protected and intact.

So, I guess, what would be portrayed by mainstream medicine as dysfunctional isnt really so. And what really is dysfunctional could just be the response of medicine to try to intervene when it shouldn't. In all the ways modern medicine could.

Maybe something to do with tonicity, vascular tone and everything thereafter. Onset in reverse, I wonder what causes that.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11293686/
(Only a sample.)

If "the next pandemic" had an energy mandate as or opposed to a vaccine mandate. I wonder what would happen.

the study in women athletes had them taking ridiculously high doses, something like 1g a day of TTFD iirc.

it is dopamingeric, the first time i took a 25mg alinamin f tablet i got pronounced euphoria. it’s popular in japan.

@Mauritio said in Random, interesting studies:

Anybody tried bees bread ?

In this study it did wonders for steroid health.
They gave mice on a HFD about 5-7g(HED) of bees bread and it completely rescued the levels of their steroidogenic enzymes.
Not only that, in many cases, giving them bees bread, increased the values above the normal control group.

Testosterone was increased by about 60% above control levels.
StaR mRNA levels doubled !
Unfortunately estrogen was increased as well, but only to the level of the control group not above that.

1000014499.jpg

https://journals.physiology.org/doi/full/10.1152/ajpendo.00093.2021?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org

I was wondering where the strong androgenic effect from this study was coming from, it seemed hard to believe that it was only from an antioxidant effect.

I think I found the answer.
IL-10 has been shown to be responsible for the 5-10x increase in Testosterone from L. Reuteri in animal studies.
https://bioenergetic.forum/topic/2188/l-reuteri/50?_=1747639248664

And bee bread drastically increased Il-10 in this study.

Compared to the control group the mrna increased about 10x and compared to the obese high fat group probably 30x . So that might be part of the androgenic effect.

I took 2.5g yesterday and today my muscle look insanely full, also notice higher libido and drive.

Screenshot 2025-05-19 09.18.51.png

https://pmc.ncbi.nlm.nih.gov/articles/PMC8868291/#sec3-antioxidants-11-00255

@haidut

How timely. 🙂

Hi Haidut, nice to see you here!

@haidut
I remember the announcement and recruiting for this study in 2020 iirc.
Then everything vanished and reportedly the project's budget was cut and the study shelved.
WTF was going on there. How did they finish it anyway? Who allowed them to now release their results? Too many polito-economic-corruptory questions.

@haidut Wow no surprise the SSRIS are really from the bad guys.

Do you have a recommendations for what a person with PSSD should do?
(Post ssri sexual dysfunction)
Would love to hear your thoughts…….

Thanks

@wester130 i think we’re talking about two different types of massage intensity. I began just rubbing by pushing my fingers to the top of the scalp to make it feel good, and trying to move the scalp from side to side, as if to stretch (pleasure is a good sign of a safe stimulation imo). With time, moving the scalp can become a small victory. I can now pinch my scalp skin between two fingers on my well rested days, but many days i cannot… i just rub my fingers on it and move the skin how ever much it will.

@CrumblingCookie I wouldn't call it anti-serotonergic , the mood lift felt more like a neurosteroid boost. Which is a little different from a dopamine boost. Both are good though.

Not sure about it's androgenicity , I didn't experience any detrimental effects . But I only tried it twice and I was also sick with a cold so not the best test run.
I certainly would be willing to try it again if it wasn't for the constipation, but I'm sure I'll give it another go.

Ive tried the old version of gonadin today with phytol in it. that was quite nice . I'm also having great results with diosgenin in the last months.

@Mauritio heh

Mailloux, R. J., Gardiner, D., & O’Brien, M. (2016). 2-Oxoglutarate dehydrogenase is a more significant source of O2·−/H2O2 than pyruvate dehydrogenase in cardiac and liver tissue. Free Radical Biology and Medicine, 97, 501–512. https://doi.org/10.1016/j.freeradbiomed.2016.06.014

Maj, M. C., Cameron, J. M., & Robinson, B. H. (2006). Pyruvate dehydrogenase phosphatase deficiency: Orphan disease or an under-diagnosed condition? Molecular and Cellular Endocrinology, 249(1–2), 1–9. https://doi.org/10.1016/j.mce.2006.02.003

Masini, T., Birkaya, B., Van Dijk, S., Mondal, M., Hekelaar, J., Jäger, M., Terwisscha Van Scheltinga, A. C., Patel, M. S., Hirsch, A. K. H., & Moman, E. (2016). Furoates and thenoates inhibit pyruvate dehydrogenase kinase 2 allosterically by binding to its pyruvate regulatory site. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(sup4), 170–175. https://doi.org/10.1080/14756366.2016.1201812

Mathias, R. A., Greco, T. M., Oberstein, A., Budayeva, H. G., Chakrabarti, R., Rowland, E. A., Kang, Y., Shenk, T., & Cristea, I. M. (2014). Sirtuin 4 Is a Lipoamidase Regulating Pyruvate Dehydrogenase Complex Activity. Cell, 159(7), 1615–1625. https://doi.org/10.1016/j.cell.2014.11.046

Mayr, J. A., Feichtinger, R. G., Tort, F., Ribes, A., & Sperl, W. (2014). Lipoic acid biosynthesis defects. Journal of Inherited Metabolic Disease, 37(4), 553–563. https://doi.org/10.1007/s10545-014-9705-8

McFate, T., Mohyeldin, A., Lu, H., Thakar, J., Henriques, J., Halim, N. D., Wu, H., Schell, M. J., Tsang, T. M., Teahan, O., Zhou, S., Califano, J. A., Jeoung, N. H., Harris, R. A., & Verma, A. (2008). Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer Cells. Journal of Biological Chemistry, 283(33), 22700–22708. https://doi.org/10.1074/jbc.M801765200

McKelvey, K. J., Wilson, E. B., Short, S., Melcher, A. A., Biggs, M., Diakos, C. I., & Howell, V. M. (2021). Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma. Frontiers in Oncology, 11, 633210. https://doi.org/10.3389/fonc.2021.633210

McLean, P., Kunjara, S., Greenbaum, A. L., Gumaa, K., López-Prados, J., Martin-Lomas, M., & Rademacher, T. W. (2008). Reciprocal Control of Pyruvate Dehydrogenase Kinase and Phosphatase by Inositol Phosphoglycans: Dynamic State Set by “Push-Pull” System. Journal of Biological Chemistry, 283(48), 33428–33436. https://doi.org/10.1074/jbc.M801781200

Mehr, A. (2023). Structural interrogation of enzyme mechanism and dynamics [Georg-August-University Göttingen]. https://doi.org/10.53846/goediss-9875

Milne, J. L. S. (2002). Molecular architecture and mechanism of an icosahedral pyruvate dehydrogenase complex: A multifunctional catalytic machine. The EMBO Journal, 21(21), 5587–5598. https://doi.org/10.1093/emboj/cdf574

Milne, J. L. S., Wu, X., Borgnia, M. J., Lengyel, J. S., Brooks, B. R., Shi, D., Perham, R. N., & Subramaniam, S. (2006). Molecular Structure of a 9-MDa Icosahedral Pyruvate Dehydrogenase Subcomplex Containing the E2 and E3 Enzymes Using Cryoelectron Microscopy. Journal of Biological Chemistry, 281(7), 4364–4370. https://doi.org/10.1074/jbc.M504363200

Moore, J. D., Staniszewska, A., Shaw, T., D’Alessandro, J., Davis, B., Surgenor, A., Baker, L., Matassova, N., Murray, J., Brough, P., Wood, M., & Mahon, P. C. (n.d.). VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells.

Motojima, K., & Seto, K. (2003). Fibrates and Statins Rapidly and Synergistically Induce Pyruvate Dehydrogenase Kinase 4 mRNA in the Liver and Muscles of Mice. Biological and Pharmaceutical Bulletin, 26(7), 954–958. https://doi.org/10.1248/bpb.26.954

Nemeria, N., Arjunan, P., Brunskill, A., Sheibani, F., Wei, W., Yan, Zhang, S., Jordan, F., & Furey, W. (2002). Histidine 407, a Phantom Residue in the E1 Subunit of the Escherichia coli Pyruvate Dehydrogenase Complex, Activates Reductive Acetylation of Lipoamide on the E2 Subunit. An Explanation for Conservation of Active Sites between the E1 Subunit and Transketolase. Biochemistry, 41(52), 15459–15467. https://doi.org/10.1021/bi0205909

Nemeria, N. S., Ambrus, A., Patel, H., Gerfen, G., Adam-Vizi, V., Tretter, L., Zhou, J., Wang, J., & Jordan, F. (2014). Human 2-Oxoglutarate Dehydrogenase Complex E1 Component Forms a Thiamin-derived Radical by Aerobic Oxidation of the Enamine Intermediate. Journal of Biological Chemistry, 289(43), 29859–29873. https://doi.org/10.1074/jbc.M114.591073

Nemeria, N. S., Chakraborty, S., Balakrishnan, A., & Jordan, F. (2009). Reaction mechanisms of thiamin diphosphate enzymes: Defining states of ionization and tautomerization of the cofactor at individual steps. The FEBS Journal, 276(9), 2432–3446. https://doi.org/10.1111/j.1742-4658.2009.06964.x

Norton, L., & DeFronzo, R. (2014). Skeletal Muscle Glucose Metabolism and Insulin Resistance. In Pathobiology of Human Disease (pp. 477–487). Elsevier. https://doi.org/10.1016/B978-0-12-386456-7.02003-7

Olson, M. S., Hampson, R. K., & Craig, F. (1986). Regulation of the hepatic glycine-cleavage system. Biochemical Society Transactions, 14(6), 1004–1005. https://doi.org/10.1042/bst0141004

O’Reilly, F. J., Graziadei, A., Forbrig, C., Bremenkamp, R., Charles, K., Lenz, S., Elfmann, C., Fischer, L., Stülke, J., & Rappsilber, J. (2023). Protein complexes in cells by AI‐assisted structural proteomics. Molecular Systems Biology, 19(4), e11544. https://doi.org/10.15252/msb.202311544

Orfali, K. A., Fryer, L. G. D., Holness, M. J., & Sugden, M. C. (1993). Long‐term regulation of pyruvate dehydrogenase kinase by high‐fat feeding: Experiments in vivo and in cultured cardiomyocytes. FEBS Letters, 336(3), 501–505. https://doi.org/10.1016/0014-5793(93)80864-Q

Patel, K. P., O’Brien, T. W., Subramony, S. H., Shuster, J., & Stacpoole, P. W. (2012). The spectrum of pyruvate dehydrogenase complex deficiency: Clinical, biochemical and genetic features in 371 patients. Molecular Genetics and Metabolism, 105(1), 34–43. https://doi.org/10.1016/j.ymgme.2011.09.032

Patel, M. S., & Korotchkina, L. G. (n.d.). Regulation of the pyruvate dehydrogenase complex.

Patel, M. S., & Korotchkina, L. G. (2001). Regulation of mammalian pyruvate dehydrogenase complex by phosphorylation: Complexity of multiple phosphorylation sites and kinases. Experimental & Molecular Medicine, 33(4), 191–197. https://doi.org/10.1038/emm.2001.32

Patel, M. S., Nemeria, N. S., Furey, W., & Jordan, F. (2014). The Pyruvate Dehydrogenase Complexes: Structure-based Function and Regulation. Journal of Biological Chemistry, 289(24), 16615–16623. https://doi.org/10.1074/jbc.R114.563148

Patel, M. S., & Roche, T. E. (1990). Molecular biology and biochemistry of pyruvate dehydrogenase complexes. The FASEB Journal, 4(14), 3224–3233. https://doi.org/10.1096/fasebj.4.14.2227213

Pavlu-Pereira, H., Lousa, D., Tomé, C. S., Florindo, C., Silva, M. J., De Almeida, I. T., Leandro, P., Rivera, I., & Vicente, J. B. (2021). Structural and functional impact of clinically relevant E1α variants causing pyruvate dehydrogenase complex deficiency. Biochimie, 183, 78–88. https://doi.org/10.1016/j.biochi.2021.02.007

Pawelczyk, T., & Olson, M. S. (1995). Changes in the structure of pyruvate dehydrogenase complex induced by mono- and divalent ions. The International Journal of Biochemistry & Cell Biology, 27(5), 513–521. https://doi.org/10.1016/1357-2725(95)00006-B

Paxton, R., Scislowski, P. W., Davis, E. J., & Harris, R. A. (1986). Role of branched-chain 2-oxo acid dehydrogenase and pyruvate dehydrogenase in 2-oxobutyrate metabolism. Biochemical Journal, 234(2), 295–303. https://doi.org/10.1042/bj2340295

Pei, X. Y., Titman, C. M., Frank, R. A. W., Leeper, F. J., & Luisi, B. F. (2008). Snapshots of Catalysis in the E1 Subunit of the Pyruvate Dehydrogenase Multienzyme Complex. Structure, 16(12), 1860–1872. https://doi.org/10.1016/j.str.2008.10.009

Perham, R. N. (2000). Swinging Arms and Swinging Domains in Multifunctional Enzymes: Catalytic Machines for Multistep Reactions. Annual Review of Biochemistry, 69(1), 961–1004. https://doi.org/10.1146/annurev.biochem.69.1.961

Peters, S. J., & LeBlanc, P. J. (2004). Metabolic aspects of low carbohydrate diets and exercise. Nutrition & Metabolism, 1(1), 7. https://doi.org/10.1186/1743-7075-1-7

Pin, F., Novinger, L. J., Huot, J. R., Harris, R. A., Couch, M. E., O’Connell, T. M., & Bonetto, A. (2019). PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. The FASEB Journal, 33(6), 7778–7790. https://doi.org/10.1096/fj.201802799R

Prabhu, A., Sarcar, B., Miller, C. R., Kim, S.-H., Nakano, I., Forsyth, P., & Chinnaiyan, P. (2015). Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. Neuro-Oncology, 17(9), 1220–1230. https://doi.org/10.1093/neuonc/nou369

Prajapati, S., Haselbach, D., Wittig, S., Patel, M. S., Chari, A., Schmidt, C., Stark, H., & Tittmann, K. (2019). Structural and Functional Analyses of the Human PDH Complex Suggest a “Division-of-Labor” Mechanism by Local E1 and E3 Clusters. Structure, 27(7), 1124-1136.e4. https://doi.org/10.1016/j.str.2019.04.009

Prajapati, S., Rabe Von Pappenheim, F., & Tittmann, K. (2022). Frontiers in the enzymology of thiamin diphosphate-dependent enzymes. Current Opinion in Structural Biology, 76, 102441. https://doi.org/10.1016/j.sbi.2022.102441

Priestman, D. A., Orfali, K. A., & Sugden, M. C. (1996). Pyruvate inhibition of pyruvate dehydrogenase kinase: Effects of progressive starvation and hyperthyroidism in vivo, and of dibutyryl cyclic AMP and fatty acids in cultured cardiac myocytes. FEBS Letters, 393(2–3), 174–178. https://doi.org/10.1016/0014-5793(96)00877-0

Prochownik, E. V., & Wang, H. (2021). The Metabolic Fates of Pyruvate in Normal and Neoplastic Cells. Cells, 10(4), 762. https://doi.org/10.3390/cells10040762

Quinlan, C. L., Goncalves, R. L. S., Hey-Mogensen, M., Yadava, N., Bunik, V. I., & Brand, M. D. (2014). The 2-Oxoacid Dehydrogenase Complexes in Mitochondria Can Produce Superoxide/Hydrogen Peroxide at Much Higher Rates Than Complex I. Journal of Biological Chemistry, 289(12), 8312–8325. https://doi.org/10.1074/jbc.M113.545301

Roche, T. E., Baker, J. C., Yan, X., Hiromasa, Y., Gong, X., Peng, T., Dong, J., Turkan, A., & Kasten, S. A. (2001). Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. In Progress in Nucleic Acid Research and Molecular Biology (Vol. 70, pp. 33–75). Elsevier. https://doi.org/10.1016/S0079-6603(01)70013-X

Roche, T. E., & Hiromasa, Y. (2007). Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cellular and Molecular Life Sciences, 64(7–8), 830–849. https://doi.org/10.1007/s00018-007-6380-z

Roche, T. E., Hiromasa, Y., Turkan, A., Gong, X., Peng, T., Yan, X., Kasten, S. A., Bao, H., & Dong, J. (2003). Essential roles of lipoyl domains in the activated function and control of pyruvate dehydrogenase kinases and phosphatase isoform 1. European Journal of Biochemistry, 270(6), 1050–1056. https://doi.org/10.1046/j.1432-1033.2003.03468.x

Roche, T. E., & Reed, L. J. (1974). Monovalent cation requirement for ADP inhibition of pyruvate dehydrogenase kinase. Biochemical and Biophysical Research Communications, 59(4), 1341–1348. https://doi.org/10.1016/0006-291X(74)90461-6

Roosterman, D., Meyerhof, W., & Cottrell, G. S. (2018). Proton Transport Chains in Glucose Metabolism: Mind the Proton. Frontiers in Neuroscience, 12, 404. https://doi.org/10.3389/fnins.2018.00404

Sale, G. J., & Randle, P. J. (1982). Occupancy of phosphorylation sites in pyruvate dehydrogenase phosphate complex in rat heart in vivo. Relation to proportion of inactive complex and rate of re-activation by phosphatase. Biochemical Journal, 206(2), 221–229. https://doi.org/10.1042/bj2060221

Sattler, U. G. A., & Mueller-Klieser, W. (2009). The anti-oxidant capacity of tumour glycolysis. International Journal of Radiation Biology, 85(11), 963–971. https://doi.org/10.3109/09553000903258889

Saunier, E., Benelli, C., & Bortoli, S. (2016). The pyruvate dehydrogenase complex in cancer: An old metabolic gatekeeper regulated by new pathways and pharmacological agents. International Journal of Cancer, 138(4), 809–817. https://doi.org/10.1002/ijc.29564

Schell, J. C., Olson, K. A., Jiang, L., Hawkins, A. J., Van Vranken, J. G., Xie, J., Egnatchik, R. A., Earl, E. G., DeBerardinis, R. J., & Rutter, J. (2014). A Role for the Mitochondrial Pyruvate Carrier as a Repressor of the Warburg Effect and Colon Cancer Cell Growth. Molecular Cell, 56(3), 400–413. https://doi.org/10.1016/j.molcel.2014.09.026

Schell, J. C., Wisidagama, D. R., Bensard, C., Zhao, H., Wei, P., Tanner, J., Flores, A., Mohlman, J., Sorensen, L. K., Earl, C. S., Olson, K. A., Miao, R., Waller, T. C., Delker, D., Kanth, P., Jiang, L., DeBerardinis, R. J., Bronner, M. P., Li, D. Y., … Rutter, J. (2017). Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism. Nature Cell Biology, 19(9), 1027–1036. https://doi.org/10.1038/ncb3593

Schoonjans, C. A., Joudiou, N., Brusa, D., Corbet, C., Feron, O., & Gallez, B. (2020). Acidosis-induced metabolic reprogramming in tumor cells enhances the anti-proliferative activity of the PDK inhibitor dichloroacetate. Cancer Letters, 470, 18–28. https://doi.org/10.1016/j.canlet.2019.12.003

Schröder-Tittmann, K., Meyer, D., Arens, J., Wechsler, C., Tietzel, M., Golbik, R., & Tittmann, K. (2013). Alternating Sites Reactivity Is a Common Feature of Thiamin Diphosphate-Dependent Enzymes As Evidenced by Isothermal Titration Calorimetry Studies of Substrate Binding. Biochemistry, 52(15), 2505–2507. https://doi.org/10.1021/bi301591e

Schulze, A., & Downward, J. (2011). Flicking the Warburg Switch—Tyrosine Phosphorylation of Pyruvate Dehydrogenase Kinase Regulates Mitochondrial Activity in Cancer Cells. Molecular Cell, 44(6), 846–848. https://doi.org/10.1016/j.molcel.2011.12.004

Schwartz. (2010). A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: Preliminary results. Oncology Reports, 23(5). https://doi.org/10.3892/or_00000778

Schwer, B., Eckersdorff, M., Li, Y., Silva, J. C., Fermin, D., Kurtev, M. V., Giallourakis, C., Comb, M. J., Alt, F. W., & Lombard, D. B. (2009). Calorie restriction alters mitochondrial protein acetylation. Aging Cell, 8(5), 604–606. https://doi.org/10.1111/j.1474-9726.2009.00503.x

Sebastian, C., Ferrer, C., Serra, M., Choi, J.-E., Ducano, N., Mira, A., Shah, M. S., Stopka, S. A., Perciaccante, A. J., Isella, C., Moya-Rull, D., Vara-Messler, M., Giordano, S., Maldi, E., Desai, N., Capen, D. E., Medico, E., Cetinbas, M., Sadreyev, R. I., … Mostoslavsky, R. (2022). A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestine. Nature Communications, 13(1), 1503. https://doi.org/10.1038/s41467-022-29085-y

Seifert, F., Ciszak, E., Korotchkina, L., Golbik, R., Spinka, M., Dominiak, P., Sidhu, S., Brauer, J., Patel, M. S., & Tittmann, K. (2007). Phosphorylation of Serine 264 Impedes Active Site Accessibility in the E1 Component of the Human Pyruvate Dehydrogenase Multienzyme Complex. Biochemistry, 46(21), 6277–6287. https://doi.org/10.1021/bi700083z

Seifert, F., Golbik, R., Brauer, J., Lilie, H., Schröder-Tittmann, K., Hinze, E., Korotchkina, L. G., Patel, M. S., & Tittmann, K. (2006). Direct Kinetic Evidence for Half-Of-The-Sites Reactivity in the E1 Component of the Human Pyruvate Dehydrogenase Multienzyme Complex through Alternating Sites Cofactor Activation. Biochemistry, 45(42), 12775–12785. https://doi.org/10.1021/bi061582l

Seim, G. L., John, S. V., Arp, N. L., Fang, Z., Pagliarini, D. J., & Fan, J. (2023). Nitric oxide-driven modifications of lipoic arm inhibit α-ketoacid dehydrogenases. Nature Chemical Biology, 19(3), 265–274. https://doi.org/10.1038/s41589-022-01153-w

Sgrignani, J., Chen, J., Alimonti, A., & Cavalli, A. (2018). How phosphorylation influences E1 subunit pyruvate dehydrogenase: A computational study. Scientific Reports, 8(1), 14683. https://doi.org/10.1038/s41598-018-33048-z

Shan, C., Kang, H.-B., Elf, S., Xie, J., Gu, T.-L., Aguiar, M., Lonning, S., Hitosugi, T., Chung, T.-W., Arellano, M., Khoury, H. J., Shin, D. M., Khuri, F. R., Boggon, T. J., & Fan, J. (2014). Tyr-94 Phosphorylation Inhibits Pyruvate Dehydrogenase Phosphatase 1 and Promotes Tumor Growth. Journal of Biological Chemistry, 289(31), 21413–21422. https://doi.org/10.1074/jbc.M114.581124

Skalidis, I., Tüting, C., & Kastritis, P. L. (2020). Unstructured regions of large enzymatic complexes control the availability of metabolites with signaling functions. Cell Communication and Signaling, 18(1), 136. https://doi.org/10.1186/s12964-020-00631-9

Škerlová, J., Berndtsson, J., Nolte, H., Ott, M., & Stenmark, P. (2021). Structure of the native pyruvate dehydrogenase complex reveals the mechanism of substrate insertion. Nature Communications, 12(1), 5277. https://doi.org/10.1038/s41467-021-25570-y

Smith, E. R., & Hewitson, T. D. (2020). TGF-β1 is a regulator of the pyruvate dehydrogenase complex in fibroblasts. Scientific Reports, 10(1), 17914. https://doi.org/10.1038/s41598-020-74919-8

Smolle, M., Prior, A. E., Brown, A. E., Cooper, A., Byron, O., & Lindsay, J. G. (2006). A New Level of Architectural Complexity in the Human Pyruvate Dehydrogenase Complex. Journal of Biological Chemistry, 281(28), 19772–19780. https://doi.org/10.1074/jbc.M601140200

Solmonson, A., & DeBerardinis, R. J. (2018). Lipoic acid metabolism and mitochondrial redox regulation. Journal of Biological Chemistry, 293(20), 7522–7530. https://doi.org/10.1074/jbc.TM117.000259

Song, J., & Jordan, F. (2012). Interchain Acetyl Transfer in the E2 Component of Bacterial Pyruvate Dehydrogenase Suggests a Model with Different Roles for Each Chain in a Trimer of the Homooligomeric Component. Biochemistry, 51(13), 2795–2803. https://doi.org/10.1021/bi201614n

Srivastava, N., Kollipara, R. K., Singh, D. K., Sudderth, J., Hu, Z., Nguyen, H., Wang, S., Humphries, C. G., Carstens, R., Huffman, K. E., DeBerardinis, R. J., & Kittler, R. (2014). Inhibition of Cancer Cell Proliferation by PPARγ Is Mediated by a Metabolic Switch that Increases Reactive Oxygen Species Levels. Cell Metabolism, 20(4), 650–661. https://doi.org/10.1016/j.cmet.2014.08.003

Stacpoole, P. W. (2011). The Dichloroacetate Dilemma: Environmental Hazard versus Therapeutic Goldmine—Both or Neither? Environmental Health Perspectives, 119(2), 155–158. https://doi.org/10.1289/ehp.1002554

Stacpoole, P. W. (2012). The pyruvate dehydrogenase complex as a therapeutic target for age‐related diseases. Aging Cell, 11(3), 371–377. https://doi.org/10.1111/j.1474-9726.2012.00805.x

Stacpoole, P. W. (2017). Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer. JNCI: Journal of the National Cancer Institute, 109(11). https://doi.org/10.1093/jnci/djx071

Stacpoole, P. W., & McCall, C. E. (2023). The pyruvate dehydrogenase complex: Life’s essential, vulnerable and druggable energy homeostat. Mitochondrion, 70, 59–102. https://doi.org/10.1016/j.mito.2023.02.007

Strowitzki, M. J., Radhakrishnan, P., Pavicevic, S., Scheer, J., Kimmer, G., Ritter, A. S., Tuffs, C., Volz, C., Vondran, F., Harnoss, J. M., Klose, J., Schmidt, T., & Schneider, M. (2019). High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases. British Journal of Cancer, 120(7), 675–688. https://doi.org/10.1038/s41416-019-0406-9

Sugden, C. M., Fryer, G. D. L., Orfali, A. K., Priestman, A. D., Donald, E., & Holness, J. M. (1998). Studies of the long-term regulation of hepatic pyruvate dehydrogenase kinase. Biochemical Journal, 329(1), 89–94. https://doi.org/10.1042/bj3290089

Sugden, M. C. (2008). PDC deletion: The way to a man’s heart disease. American Journal of Physiology-Heart and Circulatory Physiology, 295(3), H917–H919. https://doi.org/10.1152/ajpheart.00663.2008

Sugden, M. C., & Holness, M. J. (1989). Effects of re-feeding after prolonged starvation on pyruvate dehydrogenase activities in heart, diaphragm and selected skeletal muscles of the rat. Biochemical Journal, 262(2), 669–672. https://doi.org/10.1042/bj2620669

Sugden, M. C., & Holness, M. J. (2003). Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. American Journal of Physiology-Endocrinology and Metabolism, 284(5), E855–E862. https://doi.org/10.1152/ajpendo.00526.2002

Sugden, M. C., & Holness, M. J. (2006). Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases. Archives of Physiology and Biochemistry, 112(3), 139–149. https://doi.org/10.1080/13813450600935263

Sugden, M. C., Orfali, K. A., & Holness, M. J. (1995). The Pyruvate Dehydrogenase Complex: Nutrient Control and the Pathogenesis of Insulin Resistance. The Journal of Nutrition, 125, 1746S-1752S. https://doi.org/10.1093/jn/125.suppl_6.1746S

Sugden, P. H., Hutson, N. J., Kerbey, A. L., & Randle, P. J. (1978). Phosphorylation of additional sites on pyruvate dehydrogenase inhibits its re-activation by pyruvate dehydrogenase phosphate phosphatase. Biochemical Journal, 169(2), 433–435. https://doi.org/10.1042/bj1690433

Sugden, P. H., & Randle, P. J. (1978). Regulation of pig heart pyruvate dehydrogenase by phosphorylation. Studies on the subunit and phosphorylation stoicheiometries. Biochemical Journal, 173(2), 659–668. https://doi.org/10.1042/bj1730659

Sugden, P. H., & Simister, N. E. (1980). Role of multisite phosphorylation in the regulation of ox kidney pyruvate dehydrogenase complex. FEBS Letters, 111(2), 299–302. https://doi.org/10.1016/0014-5793(80)80814-3

Sutendra, G., Kinnaird, A., Dromparis, P., Paulin, R., Stenson, T. H., Haromy, A., Hashimoto, K., Zhang, N., Flaim, E., & Michelakis, E. D. (2014). A Nuclear Pyruvate Dehydrogenase Complex Is Important for the Generation of Acetyl-CoA and Histone Acetylation. Cell, 158(1), 84–97. https://doi.org/10.1016/j.cell.2014.04.046

Sutendra, G., & Michelakis, E. D. (2013). Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Frontiers in Oncology, 3. https://doi.org/10.3389/fonc.2013.00038

Takakusagi, Y., Matsumoto, S., Saito, K., Matsuo, M., Kishimoto, S., Wojtkowiak, J. W., DeGraff, W., Kesarwala, A. H., Choudhuri, R., Devasahayam, N., Subramanian, S., Munasinghe, J. P., Gillies, R. J., Mitchell, J. B., Hart, C. P., & Krishna, M. C. (2014). Pyruvate Induces Transient Tumor Hypoxia by Enhancing Mitochondrial Oxygen Consumption and Potentiates the Anti-Tumor Effect of a Hypoxia-Activated Prodrug TH-302. PLoS ONE, 9(9), e107995. https://doi.org/10.1371/journal.pone.0107995

Tovar‐Méndez, A., Miernyk, J. A., & Randall, D. D. (2003). Regulation of pyruvate dehydrogenase complex activity in plant cells. European Journal of Biochemistry, 270(6), 1043–1049. https://doi.org/10.1046/j.1432-1033.2003.03469.x

Tso, S.-C., Qi, X., Gui, W.-J., Wu, C.-Y., Chuang, J. L., Wernstedt-Asterholm, I., Morlock, L. K., Owens, K. R., Scherer, P. E., Williams, N. S., Tambar, U. K., Wynn, R. M., & Chuang, D. T. (2014). Structure-guided Development of Specific Pyruvate Dehydrogenase Kinase Inhibitors Targeting the ATP-binding Pocket. Journal of Biological Chemistry, 289(7), 4432–4443. https://doi.org/10.1074/jbc.M113.533885

Tsvetkov, P., Coy, S., Petrova, B., Dreishpoon, M., Verma, A., Abdusamad, M., Rossen, J., Joesch-Cohen, L., Humeidi, R., Spangler, R. D., Eaton, J. K., Frenkel, E., Kocak, M., Corsello, S. M., Lutsenko, S., Kanarek, N., Santagata, S., & Golub, T. R. (2022). Copper induces cell death by targeting lipoylated TCA cycle proteins. Science, 375(6586), 1254–1261. https://doi.org/10.1126/science.abf0529

Turvey, E. A., Heigenhauser, G. J. F., Parolin, M., & Peters, S. J. (2005). Elevated n-3 fatty acids in a high-fat diet attenuate the increase in PDH kinase activity but not PDH activity in human skeletal muscle. J Appl Physiol, 98.

Tüting, C., Kyrilis, F. L., Müller, J., Sorokina, M., Skalidis, I., Hamdi, F., Sadian, Y., & Kastritis, P. L. (2021). Cryo-EM snapshots of a native lysate provide structural insights into a metabolon-embedded transacetylase reaction. Nature Communications, 12(1), 6933. https://doi.org/10.1038/s41467-021-27287-4

Wada, H., Shintani, D., & Ohlrogge, J. (1997). Why do mitochondria synthesize fatty acids? Evidence for involvement in lipoic acid production. Proceedings of the National Academy of Sciences, 94(4), 1591–1596. https://doi.org/10.1073/pnas.94.4.1591

Wang, C., Ma, C., Xu, Y., Chang, S., Wu, H., Yan, C., Chen, J., Wu, Y., An, S., Xu, J., Han, Q., Jiang, Y., Jiang, Z., Chu, X., Gao, H., Zhang, X., & Chang, Y. (2025). Dynamics of the mammalian pyruvate dehydrogenase complex revealed by in-situ structural analysis. Nature Communications, 16(1), 917. https://doi.org/10.1038/s41467-025-56171-8

Wang, X., Shen, X., Yan, Y., & Li, H. (2021). Pyruvate dehydrogenase kinases (PDKs): An overview toward clinical applications. Bioscience Reports, 41(4), BSR20204402. https://doi.org/10.1042/BSR20204402

Whitley, M. J., Arjunan, P., Nemeria, N. S., Korotchkina, L. G., Park, Y.-H., Patel, M. S., Jordan, F., & Furey, W. (2018). Pyruvate dehydrogenase complex deficiency is linked to regulatory loop disorder in the αV138M variant of human pyruvate dehydrogenase. Journal of Biological Chemistry, 293(34), 13204–13213. https://doi.org/10.1074/jbc.RA118.003996

Woolbright, B. L., & Harris, R. A. (2021). PDK2: An Underappreciated Regulator of Liver Metabolism. Livers, 1(2), 82–97. https://doi.org/10.3390/livers1020008

Woolbright, B. L., Rajendran, G., Harris, R. A., & Taylor, J. A. (2019). Metabolic Flexibility in Cancer: Targeting the Pyruvate Dehydrogenase Kinase:Pyruvate Dehydrogenase Axis. Molecular Cancer Therapeutics, 18(10), 1673–1681. https://doi.org/10.1158/1535-7163.MCT-19-0079

Wu, P., Blair, P. V., Sato, J., Jaskiewicz, J., Popov, K. M., & Harris, R. A. (2000). Starvation Increases the Amount of Pyruvate Dehydrogenase Kinase in Several Mammalian Tissues. Archives of Biochemistry and Biophysics, 381(1), 1–7. https://doi.org/10.1006/abbi.2000.1946

Wynn, R. M., Kato, M., Chuang, J. L., Tso, S.-C., Li, J., & Chuang, D. T. (2008). Pyruvate Dehydrogenase Kinase-4 Structures Reveal a Metastable Open Conformation Fostering Robust Core-free Basal Activity. Journal of Biological Chemistry, 283(37), 25305–25315. https://doi.org/10.1074/jbc.M802249200

Yang, D., Gong, X., Yakhnin, A., & Roche, T. E. (1998). Requirements for the Adaptor Protein Role of Dihydrolipoyl Acetyltransferase in the Up-regulated Function of the Pyruvate Dehydrogenase Kinase and Pyruvate Dehydrogenase Phosphatase. Journal of Biological Chemistry, 273(23), 14130–14137. https://doi.org/10.1074/jbc.273.23.14130

Yihan, L., Xiaojing, W., Ao, L., Chuanjie, Z., Haofei, W., Yan, S., & Hongchao, H. (2021). SIRT5 functions as a tumor suppressor in renal cell carcinoma by reversing the Warburg effect. Journal of Translational Medicine, 19(1), 521. https://doi.org/10.1186/s12967-021-03178-6

Yin, C., He, D., Chen, S., Tan, X., & Sang, N. (2016). Exogenous pyruvate facilitates cancer cell adaptation to hypoxia by serving as an oxygen surrogate. Oncotarget, 7(30), 47494–47510. https://doi.org/10.18632/oncotarget.10202

Zachar, Z., Marecek, J., Maturo, C., Gupta, S., Stuart, S. D., Howell, K., Schauble, A., Lem, J., Piramzadian, A., Karnik, S., Lee, K., Rodriguez, R., Shorr, R., & Bingham, P. M. (2011). Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. Journal of Molecular Medicine, 89(11), 1137–1148. https://doi.org/10.1007/s00109-011-0785-8

Zhang, N., & Palmer, A. F. (2011). Development of a dichloroacetic acid‐hemoglobin conjugate as a potential targeted anti‐cancer therapeutic. Biotechnology and Bioengineering, 108(6), 1413–1420. https://doi.org/10.1002/bit.23071

Zhang, S., Hulver, M. W., McMillan, R. P., Cline, M. A., & Gilbert, E. R. (2014). The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. Nutrition & Metabolism, 11(1), 10. https://doi.org/10.1186/1743-7075-11-10

Zhang, S.-L., Hu, X., Zhang, W., & Tam, K. Y. (2016). Unexpected Discovery of Dichloroacetate Derived Adenosine Triphosphate Competitors Targeting Pyruvate Dehydrogenase Kinase To Inhibit Cancer Proliferation. Journal of Medicinal Chemistry, 59(7), 3562–3568. https://doi.org/10.1021/acs.jmedchem.5b01828

Zhang, S.-L., Hu, X., Zhang, W., Yao, H., & Tam, K. Y. (2015). Development of pyruvate dehydrogenase kinase inhibitors in medicinal chemistry with particular emphasis as anticancer agents. Drug Discovery Today, 20(9), 1112–1119. https://doi.org/10.1016/j.drudis.2015.03.012

Zhou, Z. H., Liao, W., Cheng, R. H., Lawson, J. E., McCarthy, D. B., Reed, L. J., & Stoops, J. K. (2001). Direct Evidence for the Size and Conformational Variability of the Pyruvate Dehydrogenase Complex Revealed by Three-dimensional Electron Microscopy. Journal of Biological Chemistry, 276(24), 21704–21713. https://doi.org/10.1074/jbc.M101765200

Zhou, Z. H., McCarthy, D. B., O’Connor, C. M., Reed, L. J., & Stoops, J. K. (2001). The remarkable structural and functional organization of the eukaryotic pyruvate dehydrogenase complexes. Proceedings of the National Academy of Sciences, 98(26), 14802–14807. https://doi.org/10.1073/pnas.011597698

@CrumblingCookie said in Repairing Knee Osteoarthritis and Cartilage Degeneration with the combination of Boswellia and Celery Seed::

Both celery extract and apigenin, and flavonoids in general (?), seem to promote breakdown of calcium oxalate.

Digging into this I discovered the term Chondroprotective agents. These agents "include both endogenous and synthetic chemicals." No mention of exogenous natural sources. A quick search of 2025 pulbications:

Anthocyanins and Anthocyanidins in the Management of Osteoarthritis: A Scoping Review of Current Evidence

Potential Chondroprotective Effect of Artemisia annua L. Water Extract on SW1353 Cell

Chondroprotective effect of pomegranate seed oil in papain-induced knee osteoarthritis through animal modeling

Butchered and banned.

Why China. Why.

@Mauritio Thanks 🙏

@evan-hinkle said in Visceral fat reduction by enteric-coated lactoferrin:

@Ismail hey man, doing well! I was taking 500mg Jarrow freeze-dried lactoferrin.

And just a general update: I’ve been taking the enteric coated for a few months now, and I actually think I prefer the ones I was taking before. I replicated the study above taking 300mg of the enteric coated, and really didn’t notice anything at all, (which is odd because I respond to most everything I try, (good or bad)).

TMI: I saw an undigested enteric coated lactoferrin in my stool last week, (great, they’re making it past the stomach-bad, I’m literally shitting my money away…).

Lol! I guess the enteric coating is working erm too well!

Since this event I’ve begun chewing the enteric coated pills, (now we’re really defeating the purpose, lol) and this has not made any difference. Still not noticing any effect. I’ll swap back to my old brand for a month and see what I think.

Yes will def be interesting to see how you respond if you go back again 🙂